A Phase III Clinical Trial to Investigate the Efficacy and Safety of Evogliptin When Added to Ongoing Metformin Monotherapy in Patients With Type 2 Diabetes

NCT02949193 Phase 3 COMPLETED

This is a randomized, double-blind, active-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control

Details

Lead sponsor	Dong-A ST Co., Ltd.
Phase	Phase 3
Status	COMPLETED
Enrolment	222
Start date	2013-05
Completion	2015-05

Conditions

• Type 2 Diabetes Mellitus

Interventions

• evogliptin
• Sitagliptin

Primary outcomes

• HbA1c — Change from baseline at 24 week
  unit: %

Countries

South Korea